Ernexa Therapeutics (ERNA) Return on Equity (2016 - 2025)
Historic Return on Equity for Ernexa Therapeutics (ERNA) over the last 15 years, with Q3 2025 value amounting to 4.58%.
- Ernexa Therapeutics' Return on Equity fell 62500.0% to 4.58% in Q3 2025 from the same period last year, while for Sep 2025 it was 4.58%, marking a year-over-year decrease of 62500.0%. This contributed to the annual value of 22.65% for FY2024, which is 196300.0% down from last year.
- Ernexa Therapeutics' Return on Equity amounted to 4.58% in Q3 2025, which was down 62500.0% from 58.07% recorded in Q2 2025.
- Over the past 5 years, Ernexa Therapeutics' Return on Equity peaked at 58.07% during Q2 2025, and registered a low of 8.99% during Q3 2022.
- In the last 5 years, Ernexa Therapeutics' Return on Equity had a median value of 2.23% in 2022 and averaged 4.19%.
- Over the last 5 years, Ernexa Therapeutics' Return on Equity had its largest YoY gain of 540600bps in 2025, and its largest YoY loss of -171400bps in 2025.
- Over the past 5 years, Ernexa Therapeutics' Return on Equity (Quarter) stood at 2.52% in 2021, then increased by 7bps to 2.35% in 2022, then tumbled by -218bps to 7.48% in 2023, then surged by 127bps to 2.04% in 2024, then crashed by -325bps to 4.58% in 2025.
- Its Return on Equity was 4.58% in Q3 2025, compared to 58.07% in Q2 2025 and 21.71% in Q1 2025.